中文
| Catalogue |
|
|
| Recommend Products |
Company News
- Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance 9/17/2021
- Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention ... 7/27/2021
- Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facili... 4/29/2021
- Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets 3/2/2021
- Biocon Biologics to Offer its Oncology Biosimilars through Cancer Access Partnership in ov... 2/5/2021
- Biocon Biologics Receives Rs 555 Cr Capital Injection from ADQ 1/8/2021
- Biocon Biologics Signs an MoU with CSSC in Tanzania for Mission 10 Cents 12/16/2020
- Biocon Ranked Among Top 5 Biotech Employers Globally 11/5/2020
- Biocon Biologics and Mylan Announce Launch of Semglee™ in the U.S. 9/1/2020
- Biocon Pharma and DKSH Collaborate to Commercialize Seven Generic Formulations 6/23/2020
- Biocon and Mylan Announce U.S. FDA Approval of Semglee™ 6/12/2020
- True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake 1/7/2020
- Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer 1/7/2020
- Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab 12/13/2019
- Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited 12/4/2019
- Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (Trastuzumab-dkst) 12/3/2019
- USFDA Approves Biocon’s sBLA for Pegfilgrastim New Manufacturing Facility 11/28/2019
- Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab 10/22/2018